查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
尿素循环障碍治疗市场 - 2017-2027 年全球行业规模、份额、趋势、机会和预测，按酶缺乏类型、治疗类型、给药途径、分销渠道、公司和地区细分
市场调查报告书
商品编码
1321050

尿素循环障碍治疗市场 - 2017-2027 年全球行业规模、份额、趋势、机会和预测，按酶缺乏类型、治疗类型、给药途径、分销渠道、公司和地区细分

Urea Cycle Disorders Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Enzyme Deficiency Type, By Treatment Type, By Route of Administration, By Distribution Channel, By Company, and By Region
出版日期: | 出版商: TechSci Research | 英文 111 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

预计全球尿素循环障碍治疗市场在 2023-2027 年预测期内将出现令人印象深刻的增长。主要因素包括尿素循环障碍的日益流行，以及广泛的研究和开发正在推动全球市场的增长。尿素循环障碍（UCD）是一组构成门静脉周围肝细胞尿素循环的遗传缺陷。支持市场增长的其他因素包括政府对研发活动的投资增加、主要参与者的主动性增加、大众意识的提高、更好的医疗服务的存在以及越来越多的创新诊断方法。

人群中尿素循环障碍的患病率上升

尿素循环障碍的日益流行可能会推动全球市场的增长。根据美国疾病控制与预防中心 (CDC) 发布的报告，预计每 8500 名新生儿中就有 1 人会出现尿素循环障碍。由于许多病例尚未确诊，患有该疾病的新生儿在没有得到完整诊断的情况下死亡；确切的数字仍然未知。据推测，高达 20% 的婴儿猝死综合症 (SIDS) 病例可能归因于未确诊的先天性代谢缺陷，例如尿素循环障碍，预计这将推动尿素循环障碍治疗市场的发展。

提高患者的主动性和意识

在过去的几年里，各国政府和私人组织一直在采取多项措施来促进市场的增长。不断增加的倡议，例如对研发的大量投资、提高认识计划、广泛的研究活动和临床试验以及监管机构批准的便利性是市场的支撑因素。例如，2017 年，美赞臣营养品公司 (MJN) 宣布与利洁时集团 (RB) 合併。美赞臣 (Mead Johnson) 现为 RB 旗下子公司，将其全球知名品牌（用于尿素循环障碍饮食管理的 Enfa 和 Nutramigen）纳入 RB 的消费者健康产品组合，从而巩固了其全球地位。同样，2017 年，Horizo​​n Pharma plc 推出了 UCD in Common，这是一项针对尿素循环障碍患者的倡议，为 UCD 患者、其家人和医疗保健专家提供教育、支持和互动资源。

市场细分

全球尿素循环障碍治疗市场分为酶缺乏类型、治疗类型、给药途径、分销渠道和公司。根据酶缺乏类型，市场分为氨甲酰磷酸合成酶（CPS1）、N-乙酰谷氨酸合成酶（NAGS）、鸟氨酸转氨甲酰酶（OTC缺乏）、精氨琥珀酸合成酶（ AS）、精氨琥珀酸裂解酶（AL或ASA裂解酶）、和精氨酸酶（AG）。根据治疗类型，市场分为氨基酸配方、苯丁酸、苯甲酸钠等。根据给药途径，市场分为口服和静脉注射。根据分销渠道，市场分为医院药房、零售药房和网上药房。就国家而言，由于美国尿素循环疾病病例数量不断增加，预计在预测期内美国将是一个利润丰厚的市场。

市场参与者

Bausch Health Companies Inc.、Recordati罕见疾病、Eurocept Pharmaceuticals Holding (Lucane Pharma SA)、Acer Therapeutics、Ultragenyx Pharmaceutical、Aeglea BioTherapeutics、Arcturus Therapeutics, Inc.、Orpharma Pty Ltd.、Selecta Biosciences, Inc和 Abbott Laboratories, Inc.是市场上运营的一些领先公司。

可用的定制

根据给定的市场数据，TechSci Research 可根据公司的具体需求提供定制服务。该报告可以使用以下自定义选项：

公司信息

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：COVID-19 对全球尿素循环障碍治疗市场的影响

第 4 章：客户之声

第 5 章：执行摘要

第 6 章：全球尿素循环障碍治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按酶缺乏类型（氨甲酰磷酸合成酶(CPS1)、N-乙酰谷氨酸合成酶(NAGS)、鸟氨酸转氨甲酰酶（OTC 缺乏）、精氨基琥珀酸合成酶(AS)、精氨基琥珀酸裂解酶（AL 或ASA 裂解酶）、精氨酸酶(AG)）
    • 按治疗类型（氨基酸配方、丁酸苯酯、苯甲酸钠等）
    • 按给药途径（口服与静脉注射）
    • 按分销渠道（医院药房、零售药房、网上药房）
    • 按公司划分 (2021)
    • 按地区
  • 市场地图

第 7 章：北美尿素循环障碍治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按酶缺乏类型
    • 按治疗类型
    • 按给药途径
    • 按分销渠道
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 8 章：欧洲尿素循环障碍治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按酶缺乏类型
    • 按治疗类型
    • 按给药途径
    • 按分销渠道
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第 9 章：亚太地区尿素循环障碍治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按酶缺乏类型
    • 按治疗类型
    • 按给药途径
    • 按分销渠道
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第 10 章：南美尿素循环障碍治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按酶缺乏类型
    • 按治疗类型
    • 按给药途径
    • 按分销渠道
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章：中东和非洲尿素循环障碍治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按酶缺乏类型
    • 按治疗类型
    • 按给药途径
    • 按分销渠道
    • 按国家/地区
  • MEA：国家分析
    • 南非尿素循环障碍治疗
    • 沙特阿拉伯尿素循环障碍治疗
    • 阿联酋尿素循环障碍治疗

第 12 章：市场动态

  • 司机
  • 挑战

第 13 章：市场趋势与发展

第14章：竞争格局

  • 博士健康公司
  • 罕见疾病记录
  • Eurocept 製药控股公司 (Lucane Pharma SA)
  • 宏基治疗公司
  • Ultragenyx製药公司
  • 艾格利亚生物治疗公司
  • Arcturus 治疗公司
  • 奥法玛有限公司
  • Selecta 生物科学公司
  • 雅培实验室有限公司

第 15 章：战略建议

简介目录
Product Code: 12980

The global urea cycle disorders treatment market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include the increasing prevalence of urea cycle disorder, and extensive research and development are driving the growth of the market globally. Urea cycle disorders (UCDs) are a group of genetic defects that constitute the urea cycle in the periportal liver cells. The other factors supporting the market's growth are rising investments in research and development activities by the government, increasing initiatives by key players, rising awareness among the masses, the presence of better healthcare services, and a growing number of innovative diagnostic approaches.

Rising Prevalence of urea cycle disorders among the Population

The growing prevalence of urea cycle disorders is likely to propel the growth of the market globally. According to reports published by the Centers for Disease Control and Prevention (CDC), the projected occurrence of urea cycle disorders is 1 in 8500 births. Owing to the many cases which remain undiagnosed and the newborns with the disorders die without a complete diagnosis; the exact numbers remain unknown. It is assumed that up to 20% of Sudden Infant Death Syndrome (SIDS) cases may be ascribed to an undiagnosed inborn error of metabolism, such as a urea cycle disorder which is anticipated to impel the urea cycle disorders treatment market.

Increasing Initiatives and Awareness Among Patients

Over the past few years, governments of different nations and private organizations have been taking several steps to bolster the growth of the market. Rising initiatives such as heavy investments in research and development, increase in awareness programs, extensive research activities and clinical trials, and ease in approvals by the regulatory bodies are the supporting factors for the market. For instance, in 2017, Mead Johnson Nutrition Company (MJN) declared its merger with Reckitt Benckiser Group plc (RB). Mead Johnson, now a division of RB, included its globally recognized brands, incorporating Enfa and Nutramigen, which are used in the dietary management of urea cycle disorder, to RB's consumer health portfolio, thus bolstering its position globally. Similarly, in 2017, Horizon Pharma plc launched UCD in Common, an initiative for individuals suffering from urea cycle disorder, to offer educational, supportive, and interactive resources to the patients residing with UCD, their families, and healthcare specialists.

Market Segmentation

The global urea cycle disorders treatment market is segmented into enzyme deficiency type, treatment type, route of administration, distribution channel, and company. Based on enzyme deficiency type, the market is divided into carbamyl phosphate synthetase (CPS1), N-acetyl glutamate synthetase (NAGS), ornithine transcarbamylase (OTC deficiency), argininosuccinic acid synthetase (AS), argininosuccinate lyase (AL or ASA lyase), and arginase (AG). Based on treatment type, the market is divided into amino acid formulas, phenylbutyrate, sodium benzoate, and others. Based on the route of administration, the market is divided into oral and intravenous. Based on distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising number of cases of urea cycle diseases in the country.

Market Players

Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc, and Abbott Laboratories, Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global urea cycle disorders treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type:

  • Carbamyl Phosphate Synthetase (CPS1)
  • N-Acetylglutamate Synthetase (NAGS)
  • Ornithine Transcarbamylase (OTC Deficiency)
  • Argininosuccinic Acid Synthetase (AS)
  • Argininosuccinate Lyase (AL or ASA Lyase)
  • Arginase (AG)

Urea Cycle Disorders Treatment Market, By Treatment Type:

  • Amino Acid Formulas
  • Phenylbutyrate
  • Sodium Benzoate
  • Others

Urea Cycle Disorders Treatment Market, By Route of Administration:

  • Oral
  • Intravenous

Urea Cycle Disorders Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Urea Cycle Disorders Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Urea Cycle Disorders Treatment Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Urea Cycle Disorders Treatment Market

4. Voice of Customer

5. Executive Summary

6. Global Urea Cycle Disorders Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG))
    • 6.2.2. By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others)
    • 6.2.3. By Route of Administration (Oral v/s Intravenous)
    • 6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.5. By Company (2021)
    • 6.2.6. By Region
  • 6.3. Market Map

7. North America Urea Cycle Disorders Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Enzyme Deficiency Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Urea Cycle Disorders Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Enzyme Deficiency Type
        • 7.3.1.2.2. By Treatment Type
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. Mexico Urea Cycle Disorders Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Enzyme Deficiency Type
        • 7.3.2.2.2. By Treatment Type
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. Canada Urea Cycle Disorders Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Enzyme Deficiency Type
        • 7.3.3.2.2. By Treatment Type
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel

8. Europe Urea Cycle Disorders Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Enzyme Deficiency Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Urea Cycle Disorders Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Enzyme Deficiency Type
        • 8.3.1.2.2. By Treatment Type
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. Germany Urea Cycle Disorders Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Enzyme Deficiency Type
        • 8.3.2.2.2. By Treatment Type
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. United Kingdom Urea Cycle Disorders Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Enzyme Deficiency Type
        • 8.3.3.2.2. By Treatment Type
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. Italy Urea Cycle Disorders Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Enzyme Deficiency Type
        • 8.3.4.2.2. By Treatment Type
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Spain Urea Cycle Disorders Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Enzyme Deficiency Type
        • 8.3.5.2.2. By Treatment Type
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Distribution Channel

9. Asia-Pacific Urea Cycle Disorders Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Enzyme Deficiency Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Urea Cycle Disorders Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Enzyme Deficiency Type
        • 9.3.1.2.2. By Treatment Type
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. India Urea Cycle Disorders Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Enzyme Deficiency Type
        • 9.3.2.2.2. By Treatment Type
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Japan Urea Cycle Disorders Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Enzyme Deficiency Type
        • 9.3.3.2.2. By Treatment Type
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel
    • 9.3.4. South Korea Urea Cycle Disorders Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Enzyme Deficiency Type
        • 9.3.4.2.2. By Treatment Type
        • 9.3.4.2.3. By Route of Administration
        • 9.3.4.2.4. By Distribution Channel
    • 9.3.5. Australia Urea Cycle Disorders Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Enzyme Deficiency Type
        • 9.3.5.2.2. By Treatment Type
        • 9.3.5.2.3. By Route of Administration
        • 9.3.5.2.4. By Distribution Channel

10. South America Urea Cycle Disorders Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Enzyme Deficiency Type
    • 10.2.2. By Treatment Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Urea Cycle Disorders Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Enzyme Deficiency Type
        • 10.3.1.2.2. By Treatment Type
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Argentina Urea Cycle Disorders Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Enzyme Deficiency Type
        • 10.3.2.2.2. By Treatment Type
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Colombia Urea Cycle Disorders Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Enzyme Deficiency Type
        • 10.3.3.2.2. By Treatment Type
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel

11. Middle East and Africa Urea Cycle Disorders Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Enzyme Deficiency Type
    • 11.2.2. By Treatment Type
    • 11.2.3. By Route of Administration
    • 11.2.4. By Distribution Channel
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Urea Cycle Disorders Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Enzyme Deficiency Type
        • 11.3.1.2.2. By Treatment Type
        • 11.3.1.2.3. By Route of Administration
        • 11.3.1.2.4. By Distribution Channel
    • 11.3.2. Saudi Arabia Urea Cycle Disorders Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Enzyme Deficiency Type
        • 11.3.2.2.2. By Treatment Type
        • 11.3.2.2.3. By Route of Administration
        • 11.3.2.2.4. By Distribution Channel
    • 11.3.3. UAE Urea Cycle Disorders Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Enzyme Deficiency Type
        • 11.3.3.2.2. By Treatment Type
        • 11.3.3.2.3. By Route of Administration
        • 11.3.3.2.4. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Bausch Health Companies Inc.
  • 14.2. Recordati Rare Diseases
  • 14.3. Eurocept Pharmaceuticals Holding (Lucane Pharma SA)
  • 14.4. Acer Therapeutics
  • 14.5. Ultragenyx Pharmaceutical
  • 14.6. Aeglea BioTherapeutics
  • 14.7. Arcturus Therapeutics, Inc.
  • 14.8. Orpharma Pty Ltd.
  • 14.9. Selecta Biosciences, Inc
  • 14.10. Abbott Laboratories, Inc.

15. Strategic Recommendations